Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Inclusion Criteria: * Patients must have histological or cytological diagnosis of urothelial carcinoma. Mixed histologies are permitted as long as transitional cell carcinoma is the major component (i.e. \>50% of the pathologic specimen). Pure or predominant squamous cell carcinomas are not permitted. * Patients with transitional cell carcinomas of the renal pelvis and ureter are permitted. * Patients must have metastatic or locally advanced unresectable disease. * Patients must have received one and only one prior chemotherapeutic regimen which included a platinum (at least one cycle) for metastatic/recurrent disease. Neoadjuvant or adjuvant chemotherapy will be considered to have been first line if the patient progressed within 12 months of the last dose. * Neoadjuvant/adjuvant chemotherapy (with or without a taxane) is permitted if registration is greater than 12 months since the last dose (patients must then have received one platinum containing regimen in the metastatic setting) * ECOG performance status \<= 2. * Estimated life expectancy of \>12 weeks. * Patients must have measurable disease according to RECIST criteria. * If female of childbearing potential, pregnancy test is negative within 72 hours priors to first dose of study drug. * If fertile, patient agrees to use an effective method of contraception to avoid pregnancy for the duration of the study. * Adequate organ function; Absolute neutrophil count \>1.5 x 109/L. Platelet count \>100 x109/L. Hemoglobin \>90 g/L. Total bilirubin \<1.5x upper limit of normal. Transaminases \<3x upper limit of normal (\<5x if liver metastasis are present) Calculated creatinine clearance \>40 ml/min (Cockcroft \& Gault formula) * Able to give informed consent. Exclusion Criteria: * Prior taxane therapy for metastatic disease (or \> 12 months since a taxane-containing neoadjuvant or adjuvant chemotherapy). * Pre-existing peripheral neuropathy \>1 by NCI-CTC criteria. * Pregnant or lactating females. * Uncontrolled brain or leptomeningeal involvement (treated brain metastasis permitted if both known lesions and medications e.g. steroids for that indication are stable). * History of serious or concurrent illness that might be aggravated by study treatment. * History of class II-IV congestive heart failure. * Other malignancies except adequately controlled basal cell carcinoma of the skin or carcinoma in situ of the cervix or incidental prostate cancer (T1a, Gleason \<7 PSA \<10ng/ml) or any other tumor within 5 years prior to enrollment. * Other investigational therapy or radiation therapy within 30 days before registration. * Patients not willing to employ adequate contraception for the duration of the study.